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Learning to Live together: Harnessing 
regulatory t cells to Induce organ transplant
tolerance
Andrew Y. Chang* and Nupur Bhattacharya
Stanford University School of Medicine, Stanford, California
The discovery of immune cells with regulatory effects has created considerable excitement
for their potential use in inducing tolerance to transplanted tissues. Despite the fact that
these cells possess essential functions in vivo, attempts to translate them into effective clin-
ical therapies has proved challenging due to a number of unanticipated complexities in their
behavior. This article provides a broad summary of research done to understand the largest
of the regulatory cell subtypes, namely CD4+Foxp3+ Regulatory T cells (TRegs†). Special at-
tention will be paid to current and future difficulties in using TRegs clinically, as well as room
for improvement and innovation in this field. 
IntroductIon 
Though the concept that cells with the
ability  to  downregulate  the  immune  re-
sponse has been around for a considerable
time, their existence was strongly debated
until the early 1990s, when a series of stud-
ies by Sakaguchi et al. described a popula-
tion of CD4+ T cells expressing the IL-2
receptor CD25. When athymic mice were
inoculated with T cell transfers depleted of
these CD25+ cells, they developed severe
autoimmunity in multiple organ systems
[1].  Replacement  of  CD4+CD25+  cells
suppressed the disease [1]. These “regula-
tory” T cells were subsequently suggested
to be decreased in human patients with au-
toimmune diseases such as multiple sclero-
sis [2].
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the therapeutic potential of these cells, not
only in autoimmune disease, where their
numbers were presumably decreased (and
tolerance thus broken), but also in certain in-
fections and tumors. The peripheral blood of
epithelial cancer patients has elevated circu-
lating  regulatory  T  cells,  and  numerous
mouse models have shown that manipula-
tion of this cell population can increase or
decrease immune-mediated tumor rejection
[3,4]. Their tolerogenic effect also has been
hypothesized to underlie the persistence of
certain viral infections such as hepatitis C
[5].
Particular interest in their ability to de-
termine patient tolerance to non-self anti-
gens was augmented by the discovery that
antigen-specific CD4+ regulatory T cells
were increased in mice, which tolerated al-
lografted tissues long-term [6]. A number of
human studies have since shown that a high
number of circulating TRegs in kidney and
liver transplant patients is correlated with
the stability of graft acceptance [7,8,9]. As
such,  considerable  excitement  about  the
clinical usage of TRegs in organ transplanta-
tion has been drawn up in the past decade. 
Nevertheless, a number of difficulties
have arisen concerning the translation of
these  observational  studies  into  useful
human therapies; the system is much more
complex than was initially expected. For ex-
ample, the heterogeneity, plasticity, and con-
text-dependent  activity  of  TRegs have  all
stood in the way of developing an effective,
yet safe, treatment option for transplant pa-
tients. In this review, we summarize the bi-
ology  of  CD4+  Foxp3+  TRegs and  then
discuss a framework for creating appropri-
ate therapies in relation to the challenges
presented. New approaches to apply these
concepts  in  medicine  also  will  be  high-
lighted.
current Landscape on 
combatIng transpLant 
rejectIon
The transplantation of donor tissues has
been the dramatic last resort for intractable
end-organ failure in a host of human dis-
eases. Since the 1920s, however, physicians
have observed rejection of foreign grafts, no
doubt mediated by the immune system’s
recognition of non-self protein targets [10].
Though  a  full  discussion  of  the  myriad
mechanisms by which this process occurs is
beyond the scope of this review, the major
pathways are due to effector lymphocyte
priming against donor HLA antigens, lead-
ing to cytotoxic effects (both direct cell-cell
or humoral) on the parenchyma or vascula-
ture of the graft [10]. The end result is pro-
gressive organ failure.
Before the discovery of regulatory im-
mune cells and their role in promoting tol-
erance, the goal of creating durable organ
transplant survival was focused on the elim-
ination of the effector cells hostile to trans-
planted  antigens.  This  concept  is
exemplified in the current repertoire of anti-
rejection pharmaceuticals in clinical use,
such as cyclosporine, a calcineurin inhibitor.
Unfortunately, these therapies have a num-
ber of flaws preventing them from becom-
ing acceptable permanent solutions to safe,
long-term organ transplant acceptance. First,
the drugs are nonspecific, generally damp-
ening the immune system and leading to
dangerous immunosuppressive side effects.
Second, they are only a short-term solution;
patients rarely achieve permanent tolerance
and are dependent on these drugs ― and
their side effects ― for life. 
The recognition of TRegs has not only
significantly altered the extant paradigm, but
proposed an additional reason why long-
term tolerance cannot be achieved with our
current treatment modalities: the fact that
these drugs do not distinguish between ef-
fector and regulatory players means that
though the anti-graft response is prevented,
so is the pro-graft tolerance response [11].
The ideal transplant induction therapy is
thus one that Spoerl and Li define in their
2011 review as stable, self-perpetuating, and
donor antigen-specific — factors that do not
describe our treatments at the moment [12].
Taken together, these observations strongly
suggest that more research must be con-
ducted  in  order  to  understand  how  to
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tients, either adoptively or endogenously.
reguLatory t ceLLs
Much work has been carried out since
the first studies examining broad CD4+ pop-
ulations to characterize cells with regulatory
properties. One of the first observations has
been that there are numerous groups and
subgroups of cells (both found in vivo and
experimentally induced) with suppressive
phenotypes of various potency including
CD4+CD25+Foxp3+,  CD8+Foxp3+,  Tr1
cells, Tr35 cells, CD3+CD4-CD8- “Double-
Negative” cells, and NKT cells [13,14,15].
For the purposes of this review, the term TReg
will be defined as CD4+Foxp3+ cells, since
they are the most numerous, naturally oc-
curring, and well-studied of these various
cell types.
The emphasis on CD4+Foxp3+ cells
was  heightened  by  the  discovery  of  the
Foxp3 (forkhead box P3) transcription fac-
tor, which regulates the initiation and main-
tenance of suppressive properties in TRegs.
The importance of Foxp3 was demonstrated
dramatically  in  scurfy mice,  which  are
Foxp3-deficient. These animals have a lack
of functional TRegs and suffer severe autoim-
mune effects in multiple organs [16]. A re-
lated condition in humans known as IPEX
(immunodysregulation, polyendocrinopathy,
and enteropathy, X-linked) is also associated
with a mutated Foxp3 gene [17].
CD4+Foxp3+ TRegs are divided into two
subgroups: “natural” TRegs (nTReg) and “in-
duced” TRegs (iTReg). nTRegs are born in the
thymus and are selected there by their speci-
ficities to self autoantigens, analogous to the
process used to select effector T cells in the
same organ [18]. iTRegs, on the other hand,
come from existing CD4+Foxp3- T cells in
the periphery that have been converted to
tolerate, rather than to reject, their target
antigen [19]. Their surprising origin implies
not only that foreign antigens can become
tolerated, but tolerance itself is a fluid, non-
static process that is heavily context-depen-
dent. In fact, these non-regulatory T cells are
converted to iTRegs by a number of different
factors, including TGF-ʲ, IL-2, retinoic acid
and  leukemia  inhibitory  factor  (LIF)
[20,21,22]. Furthermore, the fact that both
types of TRegs undergo a specificity-mediated
selection process means that they are highly
specific for individual antigens through en-
gagements  with  their  T  cell  Receptors
(TCRs). 
As for how TRegs suppress their target
cells, the mechanisms are likely multiple
and, as yet, not fully understood. For in-
stance, it is known that within in vitro model
systems, TRegs influence a whole host of im-
mune subtypes, including CD4+ T cells,
CD8+ T cells, natural killer T (NKT) cells,
and B cells [23]. Their effect is not limited
simply to effector cells, however, antigen-
presenting cells such as dendritic cells and
macrophages are also under TReg purview, as
are osteoblasts, mast cells, and natural killer
(NK) cells [23]. Their molecular toolbox for
achieving their actions is thus similarly di-
verse, employing secreted suppressor cy-
tokines  (e.g.,  IL-10,  TGF-￟,  IL-35),
consumption of local activating cytokines
(e.g., IL-2), cell-surface molecule signaling
(e.g., Galectin-1), and direct cell-cell killing
(via the granzyme complex) [23]. Recent
findings also show that TRegs are capable of
altering cell surfaces by trans-endocytosing
CD86 and CD80 co-stimulatory ligands on
target antigen-presenting cells [24]. This is
achieved by TReg CTLA-4, which recognizes
those molecules and causes them to be in-
ternalized and digested by the TReg. Another
feature of particular interest to transplant
physicians in TRegs is that they also exhibit
anti-inflammatory and anti-tissue remodel-
ing effects, including the inhibition of trans-
plant  vasculopathy,  a  condition  that
accelerates the rejection of a donor organ
[25].
current use of treg tHerapy In
transpLant modeLs
The potent aforementioned properties
of TRegs have attracted researchers to begin
animal and preliminary clinical tests to bring
a  therapy  closer  to  reality. A  number  of
murine studies have shown that TRegs can be
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graft tolerance [25,26,27,28]. Regulatory T
cells induced in vivo, in vitro, or expanded
ex vivo produced some impressive results,
including beating heart graft survivals past
a 100-day observation period [25]. Most of
these studies, however, have had several key
limitations. First, the animal subjects had
their existing immune systems downregu-
lated in some fashion, either by sublethal ir-
radiation or the depletion of lymphocytes or
CD4 T cells with monoclonal antibody pre-
treatment. Second, although most of these
studies were able to stave off acute trans-
plant rejection, chronic rejection still oc-
curred, or in the absence of frank chronic
rejection, histological evidence of inflam-
matory  infiltration  in  the  graft  was  still
noted.
Nevertheless, the possibility of using
immunoablation followed by bone marrow
transplantation (BMT) as a means of “reset-
ting” the immune system and transferring
tolerance to solid organ transplants has led
to several small human trials with promis-
ing results [29,30,31]. Co-transplantation of
both bone marrow and kidneys into patients
showed not only cases of long-term graft ac-
ceptance, but the complete discontinuation
of immunosuppressive therapies for some.
As for the association between BMT and
TRegs, the Kawai et al. study also detected
that Foxp3 mRNA levels in renal biopsies of
stable  immunosuppression-free  patients
were about 6 times higher than those from
the stable-with-immunosuppression group
[31]. Thus, even in the absence of more spe-
cific immune-tailoring, fostering the growth
of endogenous TRegs or possibly transferring
ex vivo TRegs could be beneficial to human
patients as well.
metHods for HarvestIng and
expandIng tregs
Creating a feasible, more specific TReg
therapy for human transplant tolerance is
primarily limited, however, by the difficulty
of expanding TReg populations to sizes large
enough to tip the effector-regulatory bal-
ance. They are not particularly numerous;
CD4+25+ regulatory cells constitute only 5
to 10 percent of peripheral CD4+ T cells
[32]. To this end, a number of experimental
strategies are being investigated for ways to
grow TRegs, both in vitro and in vivo. The first
major approach involves identifying sam-
ples highly purified for naturally occurring
TRegs. Since Foxp3 is an intracellular mole-
cule, it is not available as a cell surface
marker. As such, a cocktail of antibodies (to
CD25,  CD45RA,  CD27,  CD39,  CD49b,
FR4, or PD-1), with magnetic microbeads
and columns, must be used to select them
[33]. Thereafter, they can be expanded ex
vivo using donor or recipient antigen-pre-
senting  cells  (APCs)  or  anti-CD3/CD28
coated beads [33]. The resultant TRegs can be
reintroduced into the patient. The second
method involves the conversion of isolated
effector CD4+ T cells into induced TRegs.
This can be achieved by exposing them to a
whole host of cytokines, costimulatory fac-
tors, and growth factors, including TGF-￟,
IL-2, LIF, PD-1/PD-L1, retinoic acid, and
IDO [20,21,22,34,35,36]. As with the prior
strategy, these converted ex vivo TRegs can
then be administered to the patient. 
The third major approach would be to
expand TRegs in vivo with a variety of growth
signals, a process that is made more attrac-
tive because it avoids the difficulties of pu-
rifying  TRegs and  then  coaxing  them  to
expand  in  vitro.  However,  though  this
method  seems  as  simple  as  introducing
growth factors to the patient, the signals are
not specific for just TRegs and may result in
systemic  side  effects.  A  possible
workaround is to somehow preferentially
encourage the growth of regulatory T cells
over effector T cells; indeed, inhibiting ef-
fector T cell costimulatory pathways such as
CD28, CD40, OX40, ICOS, and CD27 with
monoclonal antibodies has been able to in-
duce tolerance to solid organ transplants in
murine experimental systems [37].
addItIonaL cHaLLenges and
opportunItIes
In addition to the issue of efficiently
generating a large number of TRegs for ther-
348 Chang and Bhattacharya: Using regulatory T cells to induce transplant toleranceapy, several factors inherent to their physi-
ology make it challenging to envision regu-
latory T cells in clinic in the near future. For
one, the difference between natural n TRegs
and induced iTRegs described above could
have significant ramifications in approaches
that exclusively use one subset of TRegs or the
other. nTRegs, because they are tailored to rec-
ognize and accept self antigens, may cause
immunodeficiencies  if  expanded  beyond
their normal repertoire of tolerance. iTRegs
avoid this problem but suffer from another
unique property: They are far more unstable
than their nTRegs brethren. iTRegs are much
more likely, under various stresses, to lose
Foxp3 expression, a process probably due to
epigenetic differences [38]. In fact, iTRegs
have been noted to turn into anti-tolerant
TH17 T cells when exposed to inflammatory
cytokines, the direct opposite of properties
desired in transplant therapy [39].
Furthermore, one must not forget that
TReg activity is the suppression of an exist-
ing active process; much of their effective-
ness  is  due  to  the  fact  that  they  can
systematically shut down effector cells. As
such, effector cells can find ways to evade
TRegs-mediated suppression. One example is
memory T cells, which maintain a certain re-
sistance to the activities of regulatory T cells
[40]. NK cells, on the other hand, take a
more direct approach by lysing TRegs [41]. As
such, therapies that seek to use TRegs for to-
lerizing patients to transplanted organs also
will need to overcome the anti-suppressive
impulses of other immune cells. For exam-
ple, Afzali et al. suggest that the resistance
of memory T cells to downregulation can be
counteracted by infusing TRegs prior to trans-
plantation, thus preempting the development
of these resilient cells [40]. NK cells could
(cautiously) be targeted for depletion with
monoclonal antibodies. 
Even if TRegs are able to be easily ex-
panded and the anti-regulatory response suf-
ficiently  reduced,  more  theoretical
challenges still exist. First, there is the risk
of uncontrolled adoptive TReg proliferation;
inadvertent suppression of the normal im-
mune  response  may  cause  unregulated
growth of infectious agents and tumor cells.
A possible way around this problem is the
engineering of self-limiting or self-destruc-
ting TRegs that stop growing after the thera-
peutic  goal  is  achieved.  It  is  yet  an
unexplored field, but a cell-surface receptor
sensitive to the tolerance-immunocompro-
mise balance (perhaps via circulating cy-
tokine detection) could be coupled to the
apoptotic pathway of a TReg to maintain an
appropriate population size. Another unre-
solved issue is that of crosstalk between the
numerous regulatory T cell subsets named
above (CD8+Foxp3+, Tr1 cells, Tr35 cells,
CD3+CD4-CD8- “Double-Negative” cells,
NKT cells). Immunosuppression is a so-
phisticated tightrope to walk, and it is highly
unlikely that the different suppressor cell
types do not communicate with each other
to decide this important concern. As of yet,
there is little experimental investigation into
this subject. 
Lastly, there is the issue of TRegs and the
current practice of medicine. As was dis-
cussed before, the extant standards of treat-
ment  involve  the  use  of  broad
immunosuppressive pharmaceuticals. Cal-
cineurin inhibitors like cyclosporine sup-
press  TCR  signaling,  blocking  the
conversion of effector T cells into induced
TRegs [42]. All is not lost, however, as other
drug classes such as mTOR inhibitors (ex-
emplified  by  rapamycin/sirolimus)  have
shown surprisingly positive effects on the
development  of  tolerance  [42]. A  mouse
model utilizing rapamycin, costimulatory
blockade, and BMT showed that the therapy
could induce mixed chimerism and subse-
quent graft tolerance without the need for
dangerous immunoablative therapies [43].
On the human side, renal transplant patients
receiving low-dose rapamycin had increased
circulating TRegs, suggesting that future im-
munosuppressive drug regimens should take
into  account  those  that  are  more  TReg-
friendly [44].
concLusIons and outLook
It is undeniable that regulatory T cells
are a powerful and important cellular actor
in  the  establishment  of  tolerance  in  the
349 Chang and Bhattacharya: Using regulatory T cells to induce transplant tolerancehuman body. Nevertheless, major strides
need to be made in overcoming both techni-
cal and mechanistic challenges to turn the
existing research into a coherent and specific
therapy for transplant patients. Particular at-
tention needs to be paid to expanding TRegs
efficiently, controlling their fickle suppres-
sive-inflammatory duality, and overcoming
endogenous resistance to regulatory action.
If these goals are achieved, a novel and con-
siderable force will have been recruited not
only for the treatment of transplant patients,
but the understanding and future conquest of
autoimmune diseases, cancer, and infection.
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